Pipeline

Code name	Generic Name	Therapeutic area (Major indications)	Development stage					Status
			Pre-clinical	Phase 1	Phase 3	Application	Approval
FKB327	Adalimumab （fully human anti-TNF-α monoclonal antibody）	Immunology (Rheumatoid arthritis, Plaque psoriasis, Crohn's disease)						EU：Approved in September 2018, as Hulio®
FKB238	Bevacizumab （humanized anti-VEGF monoclonal antibody）	Oncology (Colorectal cancer, Non-small cell lung cancer, Cervical cancer)						Phase 3 global clinical stages in non-small cell lung cancer